FDA Approves Expanded Monotherapy Label for Merck’s KEYTRUDA® (pembrolizumab)

42

KENILWORTH, N.J.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24MRK&src=ctag" target="_blank"gt;$MRKlt;/agt; lt;a href="https://twitter.com/hashtag/MRK?src=hash" target="_blank"gt;#MRKlt;/agt;–FDA Approves Expanded Monotherapy Label for Merck’s KEYTRUDA® (pembrolizumab) http://www.businesswire.com/news/home/20190411005901/en/FDA-Approves-Expanded-Monotherapy-Label-Merck%E2%80%99s-KEYTRUDA%C2%AE/?feedref=JjAwJuNHiystnCoBq_hl-QyNsUQ29c24MKpwrFSKUOTZQK86VRF04E6aMvZHPoaH7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LP6oD-t3eB0qV-nJQ-WeFyCEq7XOd8em_Uy42DWNTo2Mw==